Sales of consumables in Q1 were in line with our forecast, but total sales beat our estimates due to higher-than-expected sales of durable goods. The EBITDA margin was in line with our expectations. We foresee a high activity in the coming 12 months, with the initiation of the next clinical trial with PrimECC in Q3 and a larger trial in the heart indication in early 2019.